Stockwatch: An Ultimate Answer To A Drug Pricing Question
This article was originally published in Scrip
Last week was one of those weeks that makes you grateful that the stock markets close for the weekend. While the preparations and arrival of Pope Francis brought much of New York's Fifth Avenue and its surrounds to a standstill as Thursday wore on, it was a shame that his presence in the city could not have had the same effect on the stock markets based there.
You may also be interested in...
Biotech CEOs often express surprise when the FDA rejects their drugs. But collaborative interactions between regulators and drug sponsors count for little if the latter fail to adjust their clinical and regulatory efforts accordingly.
The era of follow-on medicinal chemistry has largely been eliminated by more comprehensive patent protection. Nowadays, investors trade on the differences in safety and efficacy for similar molecules.
A drastic risk-off pullback in the public market can close an IPO window while private biotechs aspiring for either a public debut or an acquisition by big pharma may be stymied by their stale valuations.